Investors have been left with mixed emotions regarding the stock price performance over the year, as it’s been a mixed bag. This year’s metric has recorded a Price decrease of -34.86%. However, over the past six months, we’ve seen a stronger performance of -42.13%. The price of LAB leaped by -2.56% over the last 30 days. And in the last five days, it has fallen by -1.72%.
In terms of market performance, Standard BioTools Inc had a fairly uneven. The highest value for the stock in the past year was $3.04 on 04/09/24, and the lowest value was recorded at $0.99 on 03/03/25.
52-week price history of LAB Stock
Analyzing a stock’s 52-week high and low prices can offer important information about its present condition and future outlook. Standard BioTools Inc’s current trading price is -62.50% away from its 52-week high, while its distance from the 52-week low is 15.15%. The stock’s price range during this period has varied between$0.99 and $3.04. The Standard BioTools Inc’s shares, which operate in the Healthcare, saw a trading volume of around 1.16 million for the day, a figure considerably lower than their average daily volume of 1.94 million over last three months.
Market Capitalization vs. Financial Performance: A Comparative Study
Standard BioTools Inc (LAB) has experienced a quarterly decline of -39.04% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 432.04M and boasts a workforce of 818 employees.
Combining Moving Average and Trading Volume Data for Better Market Insight
Based on Barchart.com data, the company’s moving average over the 100-day period was 1.6116, with a change in price of -0.7400. Similarly, Standard BioTools Inc recorded 1,942,814 in trading volume during the last 100 days, posting a change of -39.36%.
LAB’s Debt-to-Equity Ratio Cause for Concern? An In-Depth Look
The debt-to-equity (D/E) ratio is a significant metric that provides insights into a company’s financial state and market presence. By dividing a company’s current liabilities by its shareholders’ equity, the D/E ratio depicts the extent of debt used by a company to fund its assets relative to the value of its shareholders’ equity. At the time of writing, the total D/E ratio for LAB stands at 0.07. Similarly, the long-term debt-to-equity ratio is also 0.06.
LAB Stock Stochastic Average
Standard BioTools Inc’s raw stochastic average for the past 50 days is presently 13.04%, as of today. This marks a decrease from the raw stochastic average of the last 20 days, which was 55.56%. Additionally, the company’s Stochastic %K and %D values for the past 20 days were 63.45% and 59.09%, respectively.
